TABLE 5.
Hepatitis B e antigen (HBeAg) seroconversion rates with hepatitis B antiviral therapy
| Duration of treatment | HBeAg seroconversion rate, % (reference[s]) | HBsAg loss,%* | |
|---|---|---|---|
| Standard interferon | 16–24 weeks | 33 (HBeAg loss) (263) | NA |
| Pegylated interferon | 24–48 weeks | 29–32 (86,98) | 5–10 |
| Lamivudine | 1 year | 17–20 (111,112) | NA |
| 3 years | 40 (112) | ||
| Adefovir | 1 year | 12 (116) | NA |
| 3 years | 43 | ||
| Entecavir | 1 year | 21 (105) | 0 |
| 3 years | 39 (136) | 3 | |
| Telbivudine | 1 year | 22 (118) | 0 |
| 2 years | 33 (119) | NA | |
| Tenofovir | 1 year | 21 (100) | 3 |
| 5 years | 49 (101) | 11 |
*
Hepatitis B surface antigen (HBsAg) seroconversion rates by the end of follow-up (the duration of follow-up was not the same in all studies). NA Not applicable